News
Pharmacological Profile of Mavacamten and Key Studies of Its Use in HCM Treatment
A new addition to the treatment options for hypertrophic cardiomyopathy, approved for use in European Union countries in June 2023, is the selective reversible cardiac myosin inhibitor mavacamten. The following review summarizes its fundamental pharmacological characteristics along with the results of several crucial clinical studies and highlights the potential integration of mavacamten into clinical practice.
INFOGRAPHIC: Diagnosis and Monitoring of Patients with Hypertrophic Cardiomyopathy – Current Guidelines
What examinations should be conducted when suspecting hypertrophic cardiomyopathy, a hereditary…
Neutropenia with Thrombocytopenia after Alemtuzumab? − Case Report
Early neutropenia with thrombocytopenia is not a common side effect of alemtuzumab. However, the…
Safety of aPCC in Real Practice – Results of the BAHAS Project
What are the experiences with activated prothrombin complex concentrate (aPCC) in controlling…
Streptococcus pneumoniae Serotype 3 Continues to Be the Most Frequent Cause of Invasive Pneumococcal Diseases in the Czech Republic
After 2 years influenced by the COVID-19 pandemic, the number of cases of invasive pneumococcal…
Multimodal Treatment of Prostate Cancer in a Patient with Exceptionally Long Overall Survival − Case Report
A recently published case study by Romanian authors presents a rare instance of long-term survival…
Benefit of Short-term Androgen-deprivation Therapy Added to Radiotherapy of Localized Prostate Cancer for Long-term Survival
Androgen-deprivation therapy is associated with several adverse effects that also affect quality of…
How Does the Long-Term Effect of Beta Blocker Use Affect Clinical Outcomes in Patients After Myocardial Infarction?
In patients after myocardial infarction (MI), beta blockers (BB) still hold an important place in…
Thanks to Buccolam, the reality of suppressing convulsive seizures in children and adolescents approaches parents' ideal management
What crosses the mind of a parent when they notice their epileptic child or adolescent is having a…
Treatment of Low-Risk MDS According to NCCN Recommendations Version 1.2023
The latest recommendations from the American National Comprehensive Cancer Network (NCCN) for the…